Prime Medicine Stock (NASDAQ:PRME)

Forecast Revenue Ownership Financials Chart

Previous Close

$2.71

52W Range

$1.40 - $6.94

50D Avg

$3.34

200D Avg

$3.96

Market Cap

$509.34M

Avg Vol (3M)

$2.42M

Beta

2.31

Div Yield

PRME Company Profile

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

214

IPO Date

Oct 20, 2022

Website

PRME Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24
Reportable Segment	$4.63M	$2.98M

Fiscal year ends in Dec 25 | Currency in USD

PRME Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$4.63M	$2.98M	-
Operating Income	$-208.35M	$-202.47M	$-204.79M
Net Income	$-201.14M	$-195.88M	$-198.13M
EBITDA	$-195.76M	$-196.34M	$-186.64M
Basic EPS	$-1.35	$-1.65	$-2.18
Diluted EPS	$-1.35	$-1.65	$-2.18

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
VIR	Vir Biotechnology, Inc.
EYPT	EyePoint Pharmaceuticals, Inc.
SEPN	Septerna, Inc.
KURA	Kura Oncology, Inc.
BCAX	Bicara Therapeutics Inc. Common Stock
RZLT	Rezolute, Inc.
TYRA	Tyra Biosciences, Inc.
REPL	Replimune Group, Inc.
MRVI	Maravai LifeSciences Holdings, Inc.
PROK	ProKidney Corp.